Century Therapeutics, Inc.
IPSC Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$1.45
KIRA · Stoqly’s AI analyst, in plain words
- Century Therapeutics, Inc. had $109M of revenue in fiscal 2025, up 1,556.8% on the year before.
- Its operating margin was −15.8%, up 2,080.7 pts: of every 100 in sales, about −16 is left after running the business.
- Century Therapeutics, Inc. lost $9.6M in fiscal 2025.
- Free cash flow was −$105M in fiscal 2025, −95.9% of revenue.
Market cap
$298M
P/E
—
Revenue
$109M
Net income
−$9.6M
Free cash flow
−$105M
Operating margin
−15.8%
Century Therapeutics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+1,556.8%
Yes. Sales grew 1,556.8% last year.
Does it make a profit?
−8.8%
No. It lost money last year.
Does profit turn into cash?
−95.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Century Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Century Therapeutics, Inc.
- CIK
- 0001850119
Century Therapeutics, Inc. · IPSC
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $5.2M | $2.2M | $6.6M | $109M |
| Revenue growth | — | — | −57.0% | 194.8% | 1,556.8% |
| Operating margin | — | −2,574.2% | −6,556.9% | −2,096.5% | −15.8% |
| Net income | −$95.8M | −$131M | −$137M | −$127M | −$9.6M |
| Net margin | — | −2,518.4% | −6,115.1% | −1,920.9% | −8.8% |
| Diluted EPS | −$2.96 | −$2.96 | −$2.30 | −$1.61 | −$0.14 |
| Cash | |||||
| Cash from operations | −$89.0M | $14.1M | −$88.3M | −$110M | −$104M |
| Capital expenditure | $45.0M | $30.6M | $13.7M | $0.2M | $0.8M |
| Free cash flow | −$134M | −$16.6M | −$102M | −$110M | −$105M |
| FCF margin | — | −318.4% | −4,567.5% | −1,673.8% | −95.9% |
| Share count change | 332.9% | 0.0% | 83.1% | 32.6% | 10.1% |
| Debt and strength | |||||
| Cash and short-term investments | $223M | $315M | $173M | $189M | $117M |
| Debt incl. finance leases | $10.4M | $10.4M | — | — | — |
| Shareholders' equity | $396M | $303M | $185M | $161M | $159M |
| Current ratio | 14.6x | 10.7x | 9.9x | 1.5x | 6.0x |
| Interest coverage | −74.4x | −131.6x | −271.4x | — | — |
| Returns and quality | |||||
| Return on capital | −40.8% | — | — | — | — |
| Return on equity | −66.1% | −37.5% | −56.1% | −73.1% | −6.0% |
| Return on tangible equity | −24.2% | −43.2% | −74.0% | −99.5% | −7.7% |
| Piotroski F-score | 4 | 4 | 1 | 3 | 3 |
| Altman Z'' | 8.9 | 0.3 | −4.7 | −7.8 | −6.5 |
Insiders bought, 12 months
$0.1M
2 insiders
Insiders sold, 12 months
$0.1M
4 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Century Therapeutics, Inc. · IPSC
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.45 a share, the company is worth $298M.
Source: SEC EDGAR XBRL filings (CIK 0001850119). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.